Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV). In connection with the start of this new cohort, Arrowhead has earned a $25 million milestone payment from Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

Pasadena. CA | Posted on April 23rd, 2019

Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: “Both Arrowhead and Janssen share the aim to advance transformational medicines that achieve higher rates of functional cure with a finite treatment duration for patients with chronic hepatitis B viral infection. Beginning this new triple combination cohort in our ongoing AROHBV1001 study has the potential to generate valuable data rapidly.”

AROHBV1001 (NCT03365947) is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV.

Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by Janssen.

Hepatitis B infection is a life-threatening viral infection of the liver, which can cause cirrhosis — scarring of liver tissue — and liver cancer if the infection becomes chronic. The World Health Organization cites that hepatitis B is a global public health problem with 257 million people living with the disease, resulting in 887,000 deaths in 2015.1 While a preventive vaccine is available, cure rates for those infected remain low and most patients will endure lifelong therapy.

1 World Health Organization (WHO). Hepatitis B. July 2017. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Surrey reveals its implantable biosensor that operates without batteries May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Possible Futures

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Visualization of functional components to characterize optimal composite electrodes May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Nanomedicine

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Twisting 2D materials uncovers their superpowers: Researchers have developed a completely new method for twisting atomically thin materials, paving the way for applications of 'twistronics' based on tunable 2D materials May 12th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Engineers and scientists develop mobile technology for eye examinations: Novel photonic integrated technology will bring optical coherence tomography from stationary clinical use to mobile use May 7th, 2020

Announcements

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Visualization of functional components to characterize optimal composite electrodes May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Nanobiotechnology

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences May 1st, 2020

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given May 1st, 2020

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project